Nat. Rev. Cardiol. doi: /nrcardio

Slides:

Advertisements

Similar presentations

Nat. Rev. Cardiol. doi: /nrcardio

Advertisements

Figure 7 Mendelian randomization of overlapping exposures

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 10 Assessment of myocardial fibrosis

A B HMS derived in HNSCC HMS derived in BC c) HR for MFS [NKI data]

Nat. Rev. Cardiol. doi: /nrcardio

Figure 5 BMI and cardiorespiratory fitness levels

Figure 4 BMI and mortality in patients with heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 5 Two approaches to therapeutic genome editing

Figure 1 Experimental design

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Global rates of sodium, fruit, and vegetable intake

Figure 1 Antiplatelet and anticoagulant pathways

Figure 1 Inducers of the NLRP3 inflammasome related

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Figure 2 Size categorization of airborne pollutants

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Three-year survival rates on the basis of body composition

Figure 2 Use of CRISPR/Cas9 for genome editing

Figure 2 Physical activity and obesity levels by WHO-designated region and sex Figure 2 | Physical activity and obesity levels by WHO-designated region.

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Proactive and reactive prevention of cardiovascular disease

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Algorithm for the determination of the clinical

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Cardiovascular risk and disease across the life-course

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Volume 80, Issue 9, (November 2011)

Figure 6 Proposed arrhythmogenic right ventricular

Figure 1 Decision tree integrating the assessment,

Nat. Rev. Cardiol. doi: /nrcardio

Volume 80, Issue 1, Pages (July 2011)

Figure 5 Examples of biomarker-guided trials

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Challenges for big data applications in cardiovascular care

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Effects of cardiovascular medication on the fetus

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Association between coronary artery disease polygenic risk score and the presence of migraine Results are given as odds ratios with 95% confidence.

Figure 2 Absolute difference in seasonal peak

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Observational studies on multiple treatment strategies

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Essential features and goals of a precision medicine system

The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis Moritz C. Wyler von Ballmoos, MD, MPH, Bernhard.

Figure 3 Enrichment strategies for clinical trials

Figure 2 Impaired mitochondrial capacity and function in heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Effects of stress

Nat. Rev. Cardiol. doi: /nrcardio

Stress and coronary heart diseases

Figure 1 Novel markers of increased stroke risk in AF

Nat. Rev. Cardiol. doi: /nrcardio

Presentation transcript:

Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.189 Figure 1 Studies on stress as a risk and prognostic factor for cardiovascular disease Figure 1 | Studies on stress as a risk and prognostic factor for cardiovascular disease. Meta-analyses and large cohort studies have assessed stress as a risk factor for cardiovascular disease in the general population, in individuals at high risk of cardiovascular disease, and in patients with established cardiovascular disease. a | Except for extreme childhood stress, the associations between stress and cardiovascular end points are weak or moderate in the general population (HR <2; blue plots). b | By contrast, the associations with clinical end points are strong in high-risk populations (HR >2; red plots). c | In individuals with pre-existing cardiovascular disease, the associations of stress with recurrent events and death are moderate or strong. Statistically non-significant associations are shown with white plots. I, individual-participant data; P, data from published studies. Kivimäki, M. & Steptoe, A. (2017) Effects of stress on the development and progression of cardiovascular disease Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.189